| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
140,990,000 |
| Market
Cap: |
73.88(M) |
| Last
Volume: |
2,041,307 |
Avg
Vol: |
1,748,484 |
| 52
Week Range: |
$0.2971 - $1.74 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Sangamo BioSciences is a clinical-stage genomic medicine company focused on translating science into medicines. Co.'s clinical-stage product candidates are: Isaralgagene civaparvovec (ST-920), which is Co.'s wholly-owned gene therapy product candidate for the treatment of Fabry disease; SAR445136, which is Co.'s zinc finger nuclease gene-edited cell therapy product candidate for the treatment of sickle cell disease; TX200 for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; and Giroctocogene fitelparvovec (SB-525), which is a gene therapy product candidate for the treatment of moderately severe to severe hemophilia A.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
11,784 |
| Total Buy Value |
$0 |
$0 |
$0 |
$43,025 |
| Total People Bought |
0 |
0 |
0 |
2 |
| Total Buy Transactions |
0 |
0 |
0 |
2 |
| Total Shares Sold |
0 |
0 |
6,000,000 |
6,500,000 |
| Total Sell Value |
$0 |
$0 |
$3,000,000 |
$5,657,240 |
| Total People Sold |
0 |
0 |
1 |
1 |
| Total Sell Transactions |
0 |
0 |
1 |
3 |
| End Date |
2024-02-25 |
2023-11-24 |
2023-05-26 |
2022-05-26 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Herberts Curt A. Iii |
Senior VP & CBO |
• – – |
2017-05-11 |
4 |
AS |
$6.50 |
$4,154 |
D/D |
(639) |
39,345 |
|
- |
|
| Lanphier Edward O Ii |
Director |
– • – |
2016-12-12 |
5 |
GD |
$0.00 |
$0 |
I/I |
30,000 |
1,252,119 |
|
- |
|
| Herberts Curt A. Iii |
Senior VP & CBO |
• – – |
2016-12-12 |
4 |
D |
$3.05 |
$14,799 |
D/D |
(4,852) |
33,300 |
|
- |
|
| Herberts Curt A. Iii |
Senior VP & CBOOfficer |
• – – |
2016-11-30 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
38,152 |
|
- |
|
| Lanphier Edward O Ii |
Director |
– • – |
2016-06-13 |
4 |
D |
$6.23 |
$527,320 |
D/D |
(84,642) |
148,691 |
|
- |
|
| Lanphier Edward O Ii |
Director |
– • – |
2016-06-07 |
4 |
GD |
$0.00 |
$0 |
I/I |
50,000 |
1,175,094 |
|
- |
|
| Lanphier Edward O Ii |
Director |
– • – |
2016-03-11 |
4 |
GD |
$0.00 |
$0 |
I/I |
8,000 |
1,225,094 |
|
- |
|
| Wolff Henry Ward |
Exec VP & CFO |
• – – |
2015-12-12 |
4 |
D |
$3.05 |
$42,023 |
D/D |
(13,778) |
206,829 |
|
- |
|
| Wolff Henry Ward |
Exec VP & CFO |
• – – |
2015-12-12 |
4 |
D |
$8.68 |
$52,835 |
D/D |
(6,087) |
215,703 |
|
- |
|
| Ando Dale G |
VP, Therapeutic Dev. & CMO |
• – – |
2015-12-12 |
4 |
D |
$8.68 |
$34,720 |
D/D |
(4,000) |
107,328 |
|
- |
|
| Lanphier Edward O Ii |
President & CEO |
• • – |
2015-12-12 |
4 |
D |
$8.68 |
$113,231 |
D/D |
(13,045) |
293,906 |
|
- |
|
| Nichol Geoffrey |
Executive Vice President, R&D |
• – – |
2015-12-12 |
4 |
D |
$8.68 |
$38,053 |
D/D |
(4,384) |
159,676 |
|
- |
|
| Wolff Henry Ward |
Exec VP & CFO |
• – – |
2015-12-11 |
4 |
D |
$8.68 |
$56,611 |
D/D |
(6,522) |
221,790 |
|
- |
|
| Ando Dale G |
VP, Therapeutic Dev. & CMO |
• – – |
2015-12-11 |
4 |
D |
$8.68 |
$37,741 |
D/D |
(4,348) |
111,328 |
|
- |
|
| Lanphier Edward O Ii |
President & CEO |
• • – |
2015-12-11 |
4 |
D |
$8.68 |
$188,712 |
D/D |
(21,741) |
306,951 |
|
- |
|
| Nichol Geoffrey |
Executive Vice President, R&D |
• – – |
2015-12-11 |
4 |
D |
$8.68 |
$40,770 |
D/D |
(4,697) |
164,060 |
|
- |
|
| Nichol Geoffrey |
Executive Vice President, R&D |
• – – |
2015-12-08 |
4 |
A |
$0.00 |
$0 |
D/D |
37,500 |
175,646 |
|
- |
|
| Lanphier Edward O Ii |
President & CEO |
• • – |
2015-12-08 |
4 |
A |
$0.00 |
$0 |
D/D |
125,000 |
360,000 |
|
- |
|
| Ando Dale G |
VP, Therapeutic Dev. & CMO |
• – – |
2015-12-08 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
121,763 |
|
- |
|
| Wolff Henry Ward |
Exec VP & CFO |
• – – |
2015-12-08 |
4 |
A |
$0.00 |
$0 |
D/D |
37,500 |
235,372 |
|
- |
|
| Nichol Geoffrey |
Executive Vice President, R&D |
• – – |
2015-12-07 |
4 |
D |
$9.69 |
$66,754 |
D/D |
(6,889) |
168,757 |
|
- |
|
| Lanphier Edward O Ii |
President & CEO |
• • – |
2015-12-07 |
4 |
GD |
$0.00 |
$0 |
I/I |
13,000 |
1,172,521 |
|
- |
|
| Lanphier Edward O Ii |
President & CEO |
• • – |
2015-12-07 |
4 |
D |
$9.69 |
$303,375 |
D/D |
(31,308) |
328,692 |
|
- |
|
| Ando Dale G |
VP, Therapeutic Dev. & CMO |
• – – |
2015-12-07 |
4 |
D |
$9.69 |
$58,983 |
D/D |
(6,087) |
115,676 |
|
- |
|
| Wolff Henry Ward |
Exec VP & CFO |
• – – |
2015-12-07 |
4 |
D |
$9.69 |
$68,411 |
D/D |
(7,060) |
228,312 |
|
- |
|
1096 Records found
|
|
Page 14 of 44 |
|
|
0.04 (6.83%) 
